(thirdQuint)SPIRIT FIRST Clinical Trial of the Abbott Vascular XIENCE V Everolimus Eluting Coronary Stent System.

 The SPIRIT FIRST clinical trial will enroll approximately 60 patients and will assess the feasibility and performance of the XIENCE V(R) Everolimus Eluting Coronary Stent System in the treatment of patients with de novo native coronary artery lesions.

 In this trial, the XIENCE V(R) Everolimus Eluting Coronary Stent System will be compared to the MULTI-LINK VISION(R) metallic stent which is CE marked and FDA approved and is available for commercial use in Europe and in the United States.

 The SPIRIT FIRST Clinical trial will enroll approximately 60 patients (30 patients in the test arm and 30 patients in the control arm) with de novo native coronary artery lesions in 4 clinical sites in The Netherlands and Germany.

 SPIRIT FIRST Clinical Trial of the Abbott Vascular XIENCE V Everolimus Eluting Coronary Stent System@highlight

Prospective, randomized, controlled, single-blinded, parallel two-arm, multicenter trial.

 Test arm: XIENCE V(R) Everolimus Eluting Coronary Stent System(stent length: 18mm, diameter: 3.

0mm) Control arm: Metallic stent (MULTI-LINK VISION(R) metallic stent(stent length: 18mm, diameter: 3.

0mm) Follow-up angiographic imaging and intra vascular ultra sound (IVUS) at 180 days and 1 year